ASH News Daily - Sunday, December 11, 2011 - (Page B-15)
EXPLORING CARFILZOMIB I N R E L A P S E D M U LT I P L E M Y E L O M A
ASPIRE: a Phase III trial investigating carfilzomib-based combination therapy
• ASPIRE* compares carfilzomib plus lenalidomide and dexamethasone (CRd) and lenalidomide and dexamethasone (Rd) • The trial includes patients with multiple myeloma who have received 1 to 3 prior treatment regimens
ASPIRE is one of many ongoing trials investigating agents in the Onyx proteasome inhibitor pipeline. To learn more about the ASPIRE trial, visit www.OnyxTrials.com or
www.clinicaltrials.gov .
*ASPIRE: cArfilzomib, lenalidomide, and dexamethaSone (CRd) versus lenalidomide and dexamethasone (Rd) for the treatment of PatIents with Relapsed multiple myEloma.
©2011 Onyx Pharmaceuticals, Inc., South San Francisco, CA 1110-CARF-043-R1 June 2011
CARFILP-3280_M02_Updated_ASPIRE_ASH_News_Daily.indd 1
CARFILP-3280_M02_Updated_ASPIRE_ASH_News_Daily.indd
PRINTED @: None
10/24/11 1:37 PM
Table of Contents for the Digital Edition of ASH News Daily - Sunday, December 11, 2011
ASH News Daily - Sunday, December 11, 2011
https://www.nxtbookmedia.com